This review maps 995 original studies and 26.6 million participants comparing apixaban and rivaroxaban across AF, VTE, CKD, cirrhosis, cancer, elderly, and other high-risk populations. It delivers a clear human- and machine-ready signal: apixaban shows a more favorable bleeding profile, while rivaroxaban remains relevant in selected adherence, cost, VTE, and orthopedic contexts.
Human-verified editorial review
Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.
Abstract: This review aims to synthesize current evidence comparing apixaban and rivaroxaban regarding clinical effectiveness, safety outcomes (specifically bleeding risks), and pharmacological performance across diverse patient populations and clinical scenarios. The review utilises 995 original studies with 26655215 total participants (topic deduplicated ΣN). Across the mapped evidence, apixaban emerged as the agent with a more favorable bleeding profile compared with rivaroxaban, with hazard ratios for major bleeding ranging from 0.50 to 0.86 and for gastrointestinal bleeding from 0.33 to 0.72, while effectiveness for stroke and recurrent VTE prevention was largely comparable. This signal was consistent across diverse clinical contexts including advanced CKD, cirrhosis, diabetes, valvular heart disease, HIV, peripheral artery disease, and the very elderly, and was reinforced by pharmacokinetic observations of more stable apixaban exposure (peak-to-trough ratio 4.7 vs 16.9) and by pharmacovigilance signals favoring apixaban for hematuria, uterine bleeding, and hepatic injury. Notable countervailing signals included occasional VTE readmission and mortality findings favoring rivaroxaban, mixed endoscopic and orthopedic results, and adherence data sometimes favoring once-daily rivaroxaban, indicating that the choice between agents is not uniformly directional. The clinical implication supported by this evidence map is that apixaban may be preferentially considered in patients with elevated bleeding risk, renal or hepatic impairment, or concomitant antiplatelet therapy, while recognizing that channeling bias and the predominance of observational data temper certainty. Future research should prioritize randomized head-to-head comparisons in cirrhosis, advanced CKD, cancer-associated VTE, and women with heavy menstrual bleeding, alongside refined dosing and monitoring protocols for patients with bariatric surgery, antiseizure medication co-therapy, or extreme body weight.
Keywords: Apixaban; Rivaroxaban; Atrial Fibrillation; Venous Thromboembolism; Major Bleeding Risk; Ischemic Stroke; Gastrointestinal Bleeding; Direct Oral Anticoagulants; Comparative Effectiveness; Factor Xa Inhibitors
Review Stats
Final search date and database lock: 2026-05-02 14:39:33 CEST
Plan: Pro (expanded craft tokens; source: PubMed)
Source: PubMed
Total Abstracts/Papers: 4070
Downloaded Abstracts/Papers: 4070
Included original and non-original Abstracts/Papers (all): 1247
Included original Abstracts/Papers (Vote counting by direction of effect): 995
Reference Index (links used in paper): 177
Total participants (topic deduplicated ΣN): 26655215
Get access to the full paper
Unlock the full evidence map
The full evidence review, including the Introduction, Methods, Results, Discussion, Conclusion, figures, and complete reference index, opens after purchase or sign-in.
The Evidence Object JSON is a separate machine-readable evidence product: a concentrated synthesis of results, topic-level evidence, and discussion across original and non-original studies. It can be directly input into your LLM, agent, or RAG workflow.
[2] Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study. — https://doi.org/10.7326/m22-0511
[4] Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study. — https://doi.org/10.7326/m22-0318
[9] Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. — https://doi.org/10.7326/m21-0717
[10] Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study. — https://doi.org/10.7326/m23-3067
[22] Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study. — https://doi.org/10.1053/j.ajkd.2023.08.017
[23] Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism. — https://doi.org/10.3390/life12050705
[30] Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. — https://doi.org/10.1016/j.thromres.2015.02.008
[31] Cost-effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting. — https://doi.org/10.57264/cer-2025-0008
[43] Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. — https://doi.org/10.7326/m19-2522
[45] Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation. — https://doi.org/10.1016/j.ipej.2020.08.002
[49] Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. — https://doi.org/10.1007/s11239-023-02926-3
[51] Comparison of apixaban and rivaroxaban for anticoagulant effect after lumbar spine surgery: a single-center report. — https://doi.org/10.4155/fsoa-2017-0123
[52] Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK. — https://doi.org/10.1080/13696998.2019.1658589
[61] Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System. — https://doi.org/10.7759/cureus.85509
[68] Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease. — https://doi.org/10.1093/ehjcvp/pvaf063
[70] Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis. — https://doi.org/10.1042/bsr20180423
[76] Comparison of Apixaban, Rivaroxaban, Dabigatran, and Vitamin K Antagonists in Patients With Atrial Fibrillation and Liver Disease: A Network Meta-Analysis. — https://doi.org/10.7759/cureus.72351
[80] Effectiveness and Safety of Apixaban versus Rivaroxaban in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus. — https://doi.org/10.1055/a-1798-2116
[82] Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation. — https://doi.org/10.3390/jcm13041073
[85] Comparative effectiveness and safety of apixaban and rivaroxaban in older patients with atrial fibrillation: A population-based cohort study. — https://doi.org/10.1016/j.hrthm.2024.06.010
[89] Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. — https://doi.org/10.1093/ehjcvp/pvz086
[95] A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation. — https://doi.org/10.1177/1076029619898764
[101] Real-World Assessment of All-Cause Hospital Readmissions among Pulmonary Embolism Patients Treated With Rivaroxaban Versus Apixaban. — https://doi.org/10.1177/10760296251327592
[120] Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation. — https://doi.org/10.1161/jaha.125.044113
[123] Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. — https://doi.org/10.1111/jth.13801
[127] Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France. — https://doi.org/10.1007/s10198-022-01513-2
[130] Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. — https://doi.org/10.1007/s11239-020-02154-z
[131] Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. — https://doi.org/10.1161/circulationaha.122.060687
[133] Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis. — https://doi.org/10.1111/ijcp.13308
[134] Cost-Consequence Analysis of Apixaban Versus Rivaroxaban for Managing Patients with Venous Thromboembolism in Saudi Arabia. — https://doi.org/10.1177/10760296251318705
[142] Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. — https://doi.org/10.1016/j.amjcard.2021.02.021
[144] Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. — https://doi.org/10.1093/ehjcvp/pvab002
[148] US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total. — https://doi.org/10.57264/cer-2024-0163
[151] Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation. — https://doi.org/10.1177/1076029618802364
[153] Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study. — https://doi.org/10.1371/journal.pone.0310322
[157] Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing. — https://doi.org/10.3389/fphar.2018.01220
[158] Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. — https://doi.org/10.1007/s40264-023-01388-z
[162] Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study. — https://doi.org/10.1016/j.thromres.2024.03.024
[163] Risk of nonmajor bleeding upon use of direct oral anticoagulants for preventing and treating venous thromboembolism: A network meta-analysis. — https://doi.org/10.1177/1358863x221115213
[165] Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials. — https://doi.org/10.1016/j.ejvs.2021.10.054
[176] Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria. — https://doi.org/10.36469/9797
[177] Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. — https://doi.org/10.1016/j.clinthera.2016.01.020
[186] [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. — https://doi.org/10.18565/cardio.2014.7.43-52
[189] A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. — https://doi.org/10.18553/jmcp.2020.26.5.639
[223] Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. — https://doi.org/10.1111/ejh.13383
[225] Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. — https://doi.org/10.1001/jama.2022.1920
[226] Indirect comparison of novel Oral anticoagulants among Asians with non-Valvular atrial fibrillation in the real world setting: a network meta-analysis. — https://doi.org/10.1186/s12872-019-1165-5
[244] Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs. — https://doi.org/10.1016/j.thromres.2019.10.006
[254] Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. — https://doi.org/10.1016/s2352-3026(19)30086-9
[260] Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System. — https://doi.org/10.1016/j.vhri.2022.04.002
[262] A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile. — https://doi.org/10.1016/j.arth.2020.06.032
[273] Prevention of nNon-Vitamin K Oral Anticoagulants-Related Gastrointestinal Bleeding With Acid Suppressants: A Systematic Review and Meta-Analysis. — https://doi.org/10.1177/10760296211064897
[276] Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry. — https://doi.org/10.1055/a-2724-4458
[277] Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. — https://doi.org/10.1016/j.arth.2013.02.016
[280] Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. — https://doi.org/10.1159/000502173
[281] Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants. — https://doi.org/10.1038/s41598-020-69199-1
[282] Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study. — https://doi.org/10.1371/journal.pmed.1004754
[284] Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. — https://doi.org/10.1016/j.hrthm.2016.03.024
[286] Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. — https://doi.org/10.1111/ctr.14396
[291] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. — https://doi.org/10.1371/journal.pone.0222658
[294] Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. — https://doi.org/10.1080/03007995.2017.1347090
[298] Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review. — https://doi.org/10.1177/1076029619849103
[299] All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. — https://doi.org/10.1177/1076029617750269
[303] Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. — https://doi.org/10.3390/jcm11133788
[306] Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. — https://doi.org/10.1001/jama.2021.21222
[311] Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018. — https://doi.org/10.1093/aje/kwae268
[320] Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry. — https://doi.org/10.3390/jcm11102705
[323] Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up. — https://doi.org/10.4084/mjhid.2024.020
[325] Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study. — https://doi.org/10.3389/fcvm.2022.817826
[342] Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. — https://doi.org/10.1016/j.dld.2015.01.159
[349] Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. — https://doi.org/10.1007/s40262-013-0034-0
[365] Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective. — https://doi.org/10.1007/s10072-023-06992-6
[370] Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. — https://doi.org/10.1136/bmj.e3675
[375] Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis. — https://doi.org/10.1111/pace.14623
[381] Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. — https://doi.org/10.1016/j.pathol.2018.11.008
[385] Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy. — https://doi.org/10.1177/1060028017717019
[388] Which orally administered antithrombotic agent is most effective for preventing venous thromboembolism after total knee arthroplasty? A propensity score-matching analysis. — https://doi.org/10.1186/s43019-021-00093-4
[389] A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants. — https://doi.org/10.1016/j.ijcard.2018.06.114
[404] Remaining activity of temporary interrupted direct oral anticoagulants and its impact on intra-ablation heparinization in patients with atrial fibrillation: Comparisons across four drugs and two dose regimens. — https://doi.org/10.1111/jce.14588
[408] Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries. — https://doi.org/10.3390/jcm14093252
[409] Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. — https://doi.org/10.1111/jgs.15956
[426] Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. — https://doi.org/10.1136/gutjnl-2020-323600
[435] Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. — https://doi.org/10.1007/s10557-022-07346-8
[465] Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. — https://doi.org/10.7326/m22-3238
[476] Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients. — https://doi.org/10.1097/ftd.0000000000000356
[497] Liver injury caused by oral anticoagulants: A population-based retrospective cohort study. — https://doi.org/10.1111/liv.14559
[499] Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. — https://doi.org/10.1002/pds.5242
[506] Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism. — https://doi.org/10.1093/oncolo/oyad148
[507] Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. — https://doi.org/10.1186/s13054-022-04043-8
[514] Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation. — https://doi.org/10.1177/10742484211049919
[515] Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease. — https://doi.org/10.1161/jaha.123.034641
[524] Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. — https://doi.org/10.1016/j.ajem.2022.02.029
[605] Medications mostly associated with hematuria: assessment of the EudraVigilance and Food and Drug Administration pharmacovigilance databases entries. — https://doi.org/10.23736/s2724-6051.22.05018-2
[612] Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. — https://doi.org/10.1001/jama.2018.17242
[615] Treatment appropriateness of direct oral anticoagulants in patients with atrial fibrillation for stroke prevention: A real-world prospective study. — https://doi.org/10.1007/s00228-024-03773-8
[616] Comparison of perioperative bleeding risk between direct oral anticoagulants in transurethral resection of prostate. — https://doi.org/10.1111/bju.16478
[659] Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study. — https://doi.org/10.1016/j.acvd.2022.06.006
[686] Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. — https://doi.org/10.1016/j.hrthm.2015.04.016
[698] Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. — https://doi.org/10.4251/wjgo.v11.i10.866
[701] Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. — https://doi.org/10.1007/s40262-024-01350-x
[704] Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. — https://doi.org/10.1007/s40263-021-00795-z
[706] Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers. — https://doi.org/10.3389/fphar.2025.1542063
[756] Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. — https://doi.org/10.1038/s41598-020-68304-8
[803] Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. — https://doi.org/10.1001/jamanetworkopen.2020.3593
[808] Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage: A Multicenter, Retrospective, Observational Study Comparing the Efficacy and Safety of Andexanet and Prothrombin Complex Concentrates. — https://doi.org/10.1097/ccm.0000000000006656
[809] Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. — https://doi.org/10.1016/j.rpth.2022.100001
[829] Influence of renal function and dose of non-vitamin K antagonist oral anticoagulants on left atrial thrombus risk in patients with atrial fibrillation. Results from the multicenter LATTEE study. — https://doi.org/10.33963/v.phj.110478
[830] Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves. — https://doi.org/10.1161/jaha.124.035478
[902] Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study. — https://doi.org/10.1016/j.cgh.2020.11.029
[999] Postpolypectomy bleeding of colorectal polyps in patients with continuous warfarin and short-term interruption of direct oral anticoagulants. — https://doi.org/10.1016/j.gie.2020.09.046
[1000] Is transesophageal echocardiography necessary in patients undergoing ablation of atrial fibrillation on an uninterrupted direct oral anticoagulant regimen? Results from a prospective multicenter registry. — https://doi.org/10.1016/j.hrthm.2020.07.017
[1001] Venous thromboembolism secondary prophylaxis in elderly people (over 75-year-old) with low-dose direct oral anticoagulants: single-center Italian experience. — https://doi.org/10.1097/mbc.0000000000001321
[1046] Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. — https://doi.org/10.1016/j.cgh.2018.05.005
[1079] Risk Factors for Delayed Bleeding after Therapeutic Gastrointestinal Endoscopy in Patients Receiving Oral Anticoagulants: A Multicenter Retrospective Study. — https://doi.org/10.1159/000502952
[1115] Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database. — https://doi.org/10.1007/s40261-019-00788-3
[1128] Rates and risk factors of bleeding after gastric endoscopic submucosal dissection with continuous warfarin or 1-day withdrawal of direct oral anticoagulants. — https://doi.org/10.1111/jgh.16757
[1213] Evaluation of the impact of NOAC underdosing and exploration of bleeding risk factors in elderly patients with atrial fibrillation: artificial intelligence-based approach. — https://doi.org/10.1136/ejhpharm-2025-004610
[1242] Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China. — https://doi.org/10.3389/fphar.2021.716224
